本帖最后由 老马 于 2012-1-13 21:20 编辑 5 ?" {1 I% G' d% X
# }& D3 Q! ^+ @# l5 X/ ]
爱必妥和阿瓦斯丁的比较
" x7 Y- l* T* b. Z2 X
9 V' W4 [+ u1 c
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 J* R; A! @0 j6 U+ t
8 |6 X! P) C( R) N$ d
+ y$ Y y+ H G, {1 z! p6 }. X. B
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ \' I! `& l$ d- l* ]==================================================
, Q! D# `9 H8 ?) F% }: v+ j7 TOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)4 j: r, H1 X8 ^1 w: n
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* K! h, }' D: `: g/ z7 ]
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; ~& L1 b l3 u/ T
|